Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu
Pulmonary Fibrosis Due to COVID-19
About this trial
This is an interventional treatment trial for Pulmonary Fibrosis Due to COVID-19
Eligibility Criteria
Inclusion criteria (I) Discharged patients fulfilling the diagnostic criteria of COVID-19 (China Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7); (II) COVID-19 RNA in respiratory specimens or blood specimens of patients is negative (>2 times), assayed by real-time fluorescent polymerase chain reaction test (RT-PCR); (III) Pulmonary CT scans within 7 days showed that there were still unabsorbed inflammation or pulmonary fibrosis in the lungs; (IV) Age 18-70.
Exclusion criteria
- Patients who have undergone lung surgery that affects pulmonary function, such as pulmonary transplantation, pulmonary resection, pulmonary volume reduction, etc;
- Relying on mechanical ventilation to maintain pulmonary function, such as ventilators;
- Combined with chronic pulmonary diseases affecting pulmonary function, such as chronic obstructive pulmonary disease, other known causes of interstitial pulmonary disease;
- Patients with diseases affecting cardiac function, such as pulmonary circulation hypertension, heart failure, peripheral vascular disease, fibromyalgia, and pacemaker installation;
- Patients with severe underlying diseases affecting survival, including uncontroled cardiac, renal, digestive, hematological, neuropsychiatric, immune, metabolic diseases, malignant diseases and severe malnutrition;
- Resting heart rate >120 times/min;
- Systolic blood pressure > 180 mmHg, diastolic blood pressure > 100 mmHg;
- Unstable angina pectoris or myocardial infarction occurring within the last month;
- Severe obesity (BMI > 30 kg/m2);
- Allergic constitution, allergic to the drug components involved in the treatment program;
- Pregnant or breastfeeding women;
- Patients with disabilities who are unable to complete the efficacy evaluation questionnaires;
- Difficult collaborators with poor mental health status, suffering from mental illness, patients without self-control, unable to express clearly;
- Those who are participating in other clinical trials;
- According to the investigator's judgment, patients whose enrollment complications or poor compliance will affect the efficacy and safety evaluation.
Sites / Locations
- Shuguang Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
FZHY Group
Placebo Group
usual treatment (respiratory function rehabilitation training + Vitamin C tablets) Fuzheng Huayu tablets
usual treatment (respiratory function rehabilitation training + Vitamin C tablets) placebo